Format

Send to

Choose Destination
Malar J. 2012 Apr 27;11:135. doi: 10.1186/1475-2875-11-135.

The anaemia of Plasmodium vivax malaria.

Author information

1
Global Health Division, Menzies School of Health Research, PO Box 41096, Casuarina, NT 0811, Australia. nicholas.douglas@gmail.com

Abstract

Plasmodium vivax threatens nearly half the world's population and is a significant impediment to achievement of the millennium development goals. It is an important, but incompletely understood, cause of anaemia. This review synthesizes current evidence on the epidemiology, pathogenesis, treatment and consequences of vivax-associated anaemia. Young children are at high risk of clinically significant and potentially severe vivax-associated anaemia, particularly in countries where transmission is intense and relapses are frequent. Despite reaching lower densities than Plasmodium falciparum, Plasmodium vivax causes similar absolute reduction in red blood cell mass because it results in proportionately greater removal of uninfected red blood cells. Severe vivax anaemia is associated with substantial indirect mortality and morbidity through impaired resilience to co-morbidities, obstetric complications and requirement for blood transfusion. Anaemia can be averted by early and effective anti-malarial treatment.

PMID:
22540175
PMCID:
PMC3438072
DOI:
10.1186/1475-2875-11-135
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center